litlas
Log inCreate account

Nicholas J. Vogelzang

Active 1981–2023

217
Papers
59,631
Citations
116
h-index
217
i10-index

Citations

Citations per year for Nicholas J. Vogelzang1926: 1 citations1982: 4 citations1983: 1 citations1984: 13 citations1985: 6 citations1986: 11 citations1987: 9 citations1988: 1 citations1989: 13 citations1990: 12 citations1991: 9 citations1992: 15 citations1993: 11 citations1994: 11 citations1995: 23 citations1996: 21 citations1997: 48 citations1998: 52 citations1999: 57 citations2000: 110 citations2001: 97 citations2002: 136 citations2003: 180 citations2004: 200 citations2005: 228 citations2006: 248 citations2007: 221 citations2008: 239 citations2009: 223 citations2010: 231 citations2011: 227 citations2012: 258 citations2013: 339 citations2014: 385 citations2015: 452 citations2016: 500 citations2017: 509 citations2018: 573 citations2019: 1,912 citations2020: 2,195 citations2021: 2,106 citations2022: 1,511 citations2023: 1,218 citations2024: 1,773 citations2025: 716 citations2026: 19 citations1927–1981: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,225 citing papers, 28% of this breakdownChina: 1,795 citing papers, 8.1% of this breakdownUnited Kingdom: 1,452 citing papers, 6.5% of this breakdownItaly: 1,234 citing papers, 5.6% of this breakdownGermany: 1,119 citing papers, 5% of this breakdownFrance: 1,063 citing papers, 4.8% of this breakdownCanada: 1,003 citing papers, 4.5% of this breakdownJapan: 812 citing papers, 3.7% of this breakdownSpain: 743 citing papers, 3.3% of this breakdownNetherlands: 672 citing papers, 3% of this breakdownAustralia: 642 citing papers, 2.9% of this breakdownSwitzerland: 549 citing papers, 2.5% of this breakdown
0%28%Other 22.1%

Institutions

Fields

  • Medicine79.2%
  • Biochemistry, Genetics and Molecular Biology12.6%
  • Immunology and Microbiology4.7%
  • Engineering0.6%
  • Materials Science0.4%
  • Mathematics0.4%
  • Other2.1%

Topics

  • Cancer Immunotherapy and Biomarkers8.1%
  • Prostate Cancer Treatment and Research7.6%
  • Bladder and Urothelial Cancer Treatments5.1%
  • Prostate Cancer Diagnosis and Treatment4%
  • Immunotherapy and Immune Responses3.2%
  • Radiopharmaceutical Chemistry and Applications2.7%
  • Other69.3%

Coauthors

All papers

Open in search
  1. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    Authors: Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin - New England Journal of Medicine 2017 cited by 3,390

  2. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

    Authors: Chris Parker, Sten Nilsson, Daniel Heinrich, Svein Inge Helle, Joe M. O’Sullivan, Sophie D. Fosså, Aleš Chodacki, Paweł Wiechno, John Logue, M. Seke, Anders Widmark, Dag Clement Johannessen, Peter Hoskin, David Bottomley, Nicholas D. James, A. Solberg, Isabel Syndikus, J. Kliment, Saskia Wedel, S. Boehmer, Marcos F. Dall’Oglio, Lars Franzén, Robert E. Coleman, Nicholas J. Vogelzang, C. Gillies O'Bryan-Tear, K. Staudacher, J. Garcia‐Vargas, Minghua Shan, Øyvind S. Bruland, Oliver Sartor - New England Journal of Medicine 2013 cited by 3,343

  3. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

    Authors: Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Mario A. Eisenberger, Yu-Ning Wong, Noah M. Hahn, Manish Kohli, Matthew M. Cooney, Robert Dreicer, Nicholas J. Vogelzang, Joel Picus, Daniel H. Shevrin, Maha Hussain, Jorge A. García, Robert S. DiPaola - New England Journal of Medicine 2015 cited by 2,835

  4. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

    Authors: Christos E. Kyriakopoulos, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Noah M. Hahn, Daniel H. Shevrin, Robert Dreicer, Maha Hussain, Mario A. Eisenberger, Manish Kohli, Elizabeth R. Plimack, Nicholas J. Vogelzang, Joel Picus, Matthew M. Cooney, Jorge A. García, Robert S. DiPaola, Christopher J. Sweeney - Journal of Clinical Oncology 2018 cited by 1,106

  5. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

    Authors: Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias, Ian D. Davis, Maria De Santis, Eiji Kikuchi, Xavier García del Muro, Ugo De Giorgi, Marina Mencinger, Kouji Izumi, Stefano Panni, Mahmut Gümüş, Mustafa Özgüroğlu, Arash Rezazadeh Kalebasty, Se Hoon Park, B. Yа. Alekseev, Fabio A. Schutz, Jian-Ri Li, Dingwei Ye, Nicholas J. Vogelzang, Sandrine Bernhard, Darren Tayama, Sanjeev Mariathasan, Almut Mecke, AnnChristine Thåström, Enrique Grande - The Lancet 2020 cited by 787

  6. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer

    Authors: H. Barton Grossman, Ronald B. Natale, Catherine M. Tangen, V. O. Speights, Nicholas J. Vogelzang, Donald L. Trump, Ralph W. deVere White, Michael F. Sarosdy, David P. Wood, Derek Raghavan, E. David Crawford - New England Journal of Medicine 2003 cited by 2,644

  7. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

    Authors: Thomas Powles, Ignacio Durán, Michiel S. van der Heijden, Yohann Loriot, Nicholas J. Vogelzang, Ugo De Giorgi, Stéphane Oudard, Margitta Retz, Daniel Castellano, Aristotelis Bamias, Aude Fléchon, Gwénaëlle Gravis, Syed A. Hussain, Toshimi Takano, Ning Leng, Edward E. Kadel, Romain Banchereau, Priti S. Hegde, Sanjeev Mariathasan, Na Cui, Xiaodong Shen, Christina Louise Derleth, Marjorie C. Green, Alain Ravaud - The Lancet 2017 cited by 1,416

  8. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring aBRCA1orBRCA2Gene Alteration

    Authors: Wassim Abida, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H. Bryce, Ray McDermott, Brieuc Sautois, Nicholas J. Vogelzang, Richard Bambury, Éric Voog, Jingsong Zhang, Josep M. Piulats, Charles J. Ryan, Axel S. Merseburger, Gedske Daugaard, Axel Heidenreich, Karim Fizazi, Celestia S. Higano, Laurence E. Krieger, Cora N. Sternberg, Simon P. Watkins, Darrin Despain, Andrew D. Simmons, Andrea Loehr, Melanie Dowson, Tony Golsorkhi, Simon Chowdhury, on behalf of the TRITON2 investigators - Journal of Clinical Oncology 2020 cited by 678

  9. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

    Authors: Xīn Gào, Howard A. Burris, Jacqueline Vuky, Robert Dreicer, Oliver Sartor, Cora N. Sternberg, Ivor Percent, Maha Hussain, Arash Rezazadeh Kalebasty, John Shen, Elisabeth I. Heath, Guillermo Abesada‐Terk, Sunil Gandhi, Meredith McKean, Haolan Lu, Elmer Berghorn, Richard Gedrich, S. Debbie Chirnomas, Nicholas J. Vogelzang, Daniel P. Petrylak - Journal of Clinical Oncology 2022 cited by 186

  10. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Authors: Thomas Powles, Joseph P. Eder, Gregg Fine, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz, Joaquim Bellmunt, Howard A. Burris, Daniel P. Petrylak, Siew-leng Melinda Teng, Xiaodong Shen, Zachary Boyd, Priti S. Hegde, Daniel S. Chen, Nicholas J. Vogelzang - Nature 2014 cited by 2,430

  11. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

    Authors: Matthew D. Galsky, Noah M. Hahn, Jonathan Rosenberg, Guru Sonpavde, Thomas E. Hutson, William Oh, Robert Dreicer, Nicholas J. Vogelzang, Cora N. Sternberg, Dean F. Bajorin, Joaquim Bellmunt - Journal of Clinical Oncology 2011 cited by 688

  12. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

    Authors: Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Claude Denham, E. Kaukel, Pierre Ruffiè, U. Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold, Clet Niyikiza, Paolo Paoletti - Journal of Clinical Oncology 2003 cited by 3,063

  13. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Authors: Karim Fizazi, Howard I. Scher, Arturo Molina, Christopher J. Logothetis, Kim N., Robert J. Jones, John Staffurth, Scott North, Nicholas J. Vogelzang, Fred Saad, Paul N. Mainwaring, Stephen Harland, Oscar B. Goodman, Cora N. Sternberg, Jin Hui Li, Thian Kheoh, Christopher M. Haqq, Johann S. de Bono - The Lancet Oncology 2012 cited by 1,387

  14. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

    Authors: Charu Aggarwal, Amy Prawira, Scott Antonia, Osama E. Rahma, Anthony W. Tolcher, Roger B. Cohen, Yanyan Lou, Ralph J. Hauke, Nicholas J. Vogelzang, Dan P. Zandberg, Arash Rezazadeh Kalebasty, Victoria Atkinson, Alex A. Adjei, ­Mahesh Seetharam, Ariel E. Birnbaum, Andrew Weickhardt, Vinod Ganju, Anthony M. Joshua, Rosetta Cavallo, Linda Peng, Xiaoyu Zhang, Sanjeev Kaul, Jan Baughman, Ezio Bonvini, Paul A. Moore, S. Goldberg, Fernanda I. Arnaldez, Robert L. Ferris, Nehal J. Lakhani - Journal for ImmunoTherapy of Cancer 2022 cited by 141

  15. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

    Authors: Karim Fizazi, Ken Herrmann, Bernd J. Krause, Kambiz Rahbar, Kim N., Michael J. Morris, Oliver Sartor, Scott T. Tagawa, A. Tuba Kendi, Nicholas J. Vogelzang, Jérémie Calais, James Nagarajah, Xiao X. Wei, Vadim S. Koshkin, Jean‐Mathieu Beauregard, Brian Chang, Ray Ghouse, Michelle DeSilvio, Richard A. Messmann, Johann S. de Bono - The Lancet Oncology 2023 cited by 109

  16. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

    Authors: John P. Leonard, Matthew L. Sherman, Gerald L. Fisher, Lynn J. Buchanan, G R Larsen, Michael B. Atkins, Jeffrey A. Sosman, Janice P. Dutcher, Nicholas J. Vogelzang, John L. Ryan - 1997 cited by 814

  17. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

    Authors: Yves Fradet, Joaquim Bellmunt, David J. Vaughn, J L Lee, Lawrence Fong, Nicholas J. Vogelzang, M.Á. Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, K. Nam, Tara L. Frenkl, Rodolfo F. Perini, Ronald de Wit, Dean F. Bajorin - Annals of Oncology 2019 cited by 488

  18. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    Authors: Susan Halabi, William Kevin Kelly, Hua Ma, Hao Zhou, Nicole Solomon, Karim Fizazi, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Maha Hussain, Nicholas J. Vogelzang, Ian M. Thompson, Kim N., Johann S. de Bono, Andrew J. Armstrong, Mario A. Eisenberger, Abderrahim Fandi, Shaoyi Li, John C. Araujo, Christopher J. Logothetis, David I. Quinn, Michael J. Morris, Celestia S. Higano, Ian F. Tannock, Eric J. Small - Journal of Clinical Oncology 2016 cited by 463

  19. First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

    Authors: Daniel P. Petrylak, Xīn Gào, Nicholas J. Vogelzang, Mary Harlow Garfield, I Taylor, Marcia Dougan Moore, Ronald A. Peck, Howard A. Burris - Journal of Clinical Oncology 2020 cited by 165

  20. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

    Authors: Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donás, Robert Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Durán, Scott T. Tagawa, Yousef Zakharia, Sydney Akapame, Ademi Santiago-Walker, Manish Monga, Anne O’Hagan, Yohann Loriot, Andrea Necchi, Yohann Loriot, Se Hoon Park, Scott T. Tagawa, Aude Fléchon, B. Ya. Alexeev, Sergey Varlamov, Robert Huddart, Earle F. Burgess, Arash Rezazadeh, Arlene O. Siefker‐Radtke, Yann Vano, Donatello Gasparro, Alketa Hamzaj, Eugeniy Kopyltsov, Jesus Gracia Donas, Begoña Mellado, Omi Parikh, Peter Schatteman, Stéphane Culine, Nadine Houédé, Sylvie Zanetta, Gaetano Facchini, Giorgio V. Scagliotti, Giovanni Schinzari, Jae‐Lyun Lee, Mikhail Shkolnik, Mark T. Fleming, Monika Joshi, Peter H. O’Donnell, Herbert Stöger, Karel Decaestecker, Luc Dirix, Jean Pascal Machiels, Dephine Borchiellini, R. Delva, Frédéric Rolland, Boris Hadaschik, Margitta Retz, Eli Rosenbaum, Umberto Basso, Alessandra Mosca, Hyo Jin Lee, Dong Bok Shin, C. Cebotaru, Ignacio Durán, Víctor Moreno, José Luis Perez‐Gracia, Álvaro Pinto, Wen-Pin Su, Shian‐Shiang Wang, John D. Hainsworth, Ian D. Schnadig, Sandhya Srinivas, Nicholas J. Vogelzang, Wolfgang Loidl, Johannes Meran, M. Gross Goupil, Florence Joly, Florian Imkamp, Theodor Klotz, S. Krege, Matthias May, Wolfgang Schultze-Seemann, Arne Strauß, Uwe Zimmermann, Daniel Keizman, Avivit Peer, Avishai Sella, Rossana Berardi, Ugo De Giorgi, Cora N. Sternberg, Sun Young Rha, Iurie Bulat, А. А. Измайлов, Vsevolod Matveev, Vladimir Vladimirov, Joan Carles, Albert Font, M.I. Sáez, Isabel Syndikus and 6 more - The Lancet Oncology 2022 cited by 169

  21. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

    Authors: Thomas Powles, Peter H. O’Donnell, Christophe Massard, Hendrik-Tobias Arkenau, Terence W. Friedlander, Christopher Hoimes, Jae‐Lyun Lee, Michael Ong, Srikala S. Sridhar, Nicholas J. Vogelzang, Mayer Fishman, Jingsong Zhang, Sandy Srinivas, Jigar Parikh, Joyce Antal, Xiaoping Jin, Ashok Gupta, Yong Ben, Noah M. Hahn - JAMA Oncology 2017 cited by 846

  22. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

    Authors: Wassim Abida, David Campbell, Akash Patnaik, Jeremy Shapiro, Brieuc Sautois, Nicholas J. Vogelzang, Éric Voog, Alan H. Bryce, Ray McDermott, Francesco Ricci, Julie Rowe, Jingsong Zhang, Josep M. Piulats, Karim Fizazi, Axel S. Merseburger, Celestia S. Higano, Laurence E. Krieger, Charles J. Ryan, Felix Y. Feng, Andrew D. Simmons, Andrea Loehr, Darrin Despain, Melanie Dowson, Foad Green, Simon P. Watkins, Tony Golsorkhi, Simon Chowdhury - Clinical Cancer Research 2020 cited by 393

  23. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

    Authors: Vicky Makker, Drew Rasco, Nicholas J. Vogelzang, Marcia S. Brose, Allen Lee Cohn, James W. Mier, Christopher Di Simone, David M. Hyman, Daniel E. Stepan, Corina E. Dutcus, Emmett V. Schmidt, Matthew Guo, Pallavi Sachdev, Robert Shumaker, Carol Aghajanian, Matthew H. Taylor - The Lancet Oncology 2019 cited by 480

  24. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

    Authors: James L. Gulley, Michael Borre, Nicholas J. Vogelzang, Siobhan Ng, Neeraj Agarwal, Chris Parker, David Pook, Per Rathenborg, Thomas W. Flaig, Joan Carles, Fred Saad, Neal D. Shore, Liddy Chen, Christopher R. Heery, Winald R. Gerritsen, Frank Priou, Niels Christian Langkilde, A I Novikov, Philip W. Kantoff - Journal of Clinical Oncology 2019 cited by 278